3 years of revenue, profit, cash flow and balance-sheet history through FY2026, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2026 | $3.1B | -$333M | 54.2% | -6.1% | -9.2% | -7.2% | -$420M | — | $298M |
| 2025 | $2.7B | -$213M | 56.3% | -5.4% | -6.4% | -5.1% | -$53M | — | $11M |
| 2024 | $2.5B | -$112M | 58.2% | -2.8% | -3.2% | — | -$107M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jul '26 | $843M | $0 | 55.2% | 0.6% | 0.0% | 0.0% | -$90M | — | $207M |
| Apr '26 | $837M | -$185M | 57.3% | -11.1% | -5.1% | -4.0% | -$226M | — | $298M |
| Jan '26 | $790M | -$119M | 45.8% | -12.7% | -3.4% | -2.7% | — | — | $10M |
| Jul '25 | $723M | -$19M | 56.6% | -1.8% | -0.5% | — | -$194M | — | — |
| Apr '25 | $724M | -$172M | 55.9% | -20.4% | -5.2% | -4.1% | $26M | — | $11M |
| Jan '25 | $687M | -$10M | 57.5% | 3.1% | -0.3% | — | — | — | — |
How the market has priced MMED against its own fundamentals since 2026-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 2 years, Minimed Group, Inc.'s revenue has grown 12.1% per year. These are computed facts, not advice.
As of FY2026, Minimed Group, Inc. reported — of total debt against $298M of cash.
In FY2026, gross margin was 54.2%, operating margin -6.1%, and net margin -10.7%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.